PT - JOURNAL ARTICLE AU - Gregor Seliger AU - Lutz P. Mueller AU - Thomas Kegel AU - Eva J. Kantelhardt AU - Axel Grothey AU - Regina GroßE AU - Hans-Georg Strauss AU - Heinz Koelbl AU - Christoph Thomssen AU - Hans-Joachim Schmoll TI - Phase 2 Trial of Docetaxel, Gemcitabine, and Oxaliplatin Combination Chemotherapy in Platinum- and Paclitaxel-Pretreated Epithelial Ovarian Cancer AID - 10.1111/IGC.0b013e3181b62f38 DP - 2009 Nov 01 TA - International Journal of Gynecologic Cancer PG - 1446-1453--1446-1453 VI - 19 IP - 8 4099 - http://ijgc.bmj.com/content/19/8/1446-1453.short 4100 - http://ijgc.bmj.com/content/19/8/1446-1453.full SO - Int J Gynecol Cancer2009 Nov 01; 19 AB - Background: This phase 2 trial was designed to evaluate the efficacy and toxicity of a combination of docetaxel, gemcitabine, and oxaliplatin for platinum- and paclitaxel-pretreated epithelial ovarian cancer.Patients and Methods: Heavily pretreated patients (N = 30; median age, 61 years) received docetaxel, 55 mg/m2; gemcitabine, 500 mg/m2 (day 1); and oxaliplatin, 70 mg/m2 (day 2) biweekly. Twelve patients had platinum-sensitive disease, and 18 patients had platinum-resistant disease.Results: Median follow-up was 18.6 months. No differences in patient characteristics were observed between patients with carboplatinum-sensitive and carboplatinum-resistant disease. In patients with carboplatin-sensitive disease, an overall response (OR) of 83.3%, a progression-free survival of 10.6 months, and an overall survival of 18.9 months were observed. In patients with carboplatinum-resistant disease, an OR was seen in 38.9% with a progression-free survival of 5.3 months and an overall survival of 16.3 months. Patients with platinum-refractory disease (progression under previous carboplatinum therapy, n = 13) had an OR of 23%, whereas patients with objective response but relapse less than 6 months after carboplatinum therapy had an OR of 80.0%. Grade 3 and 4 toxicities were only observed for anemia (6.7%), neutropenia (20.0%), thrombopenia, peripheral neuropathy, and diarrhea (16.7%). No neutropenic fever or treatment-related death occurred.Conclusions: In comparison with current standard protocols, a combination of docetaxel, gemcitabine, and oxaliplatin showed considerably higher efficacy without remarkable increased toxicity; particularly for patients with early relapse after a platinum-containing therapy.